1-4 of 4
Bar Nathansohn
Close
Sort by
Journal Articles

Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease

Wei-Hsin Liu, Anat Globerson Levin, Assaf Lask, Galit Horn, Tova Waks, Bar Nathansohn Levy, Maksim Mamonkin, Zelig Eshhar, Richard E. Champlin, Yair Reisner, Esther Bachar Lustig
Journal: Blood
Blood (2023) 142 (Supplement 1): 4833.
https://doi.org/10.1182/blood-2023-175033
Published: 2023
Journal Articles

Towards Safer Allogeneic HSCT in Autoimmunity: Proof of Concept in Diabetes-Prone Mice

Rakefet Sidlik Muskatel, MD, Bar Nathansohn-Levi, PhD, Esther BACHAR Lustig, PhD, Yair Reisner, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3212.
https://doi.org/10.1182/blood-2019-124905
Published: 2019
Journal Articles

Perforin Positive Regulatory DCs In Immune Tolerance: Novel Anti-Inflammatory Players In Metabolic Syndrome

Yael Zlotnikov Klionsky, MSc, Bar Nathansohn, M.Sc, Chava Rosen, MD, Ph.D, Anna Aronovich, Ph.D, Steffen Jung, Ph.D, Elias Shezen, PhD, Oren Yifa, Yair Reisner, PhD
Journal: Blood
Blood (2013) 122 (21): 784.
https://doi.org/10.1182/blood.V122.21.784.784
Published: 2013
Journal Articles

A new approach for eradication of residual lymphoma cells by host nonreactive anti–third-party central memory CD8 T cells

Assaf Lask, Eran Ophir, Noga Or-Geva, Adva Cohen-Fredarow, Ran Afik, Yaki Eidelstein, Shlomit Reich-Zeliger, Bar Nathansohn, Matthias Edinger, Robert S. Negrin, David Hagin, Yair Reisner
Journal: Blood
Blood (2013) 121 (15): 3033–3040.
https://doi.org/10.1182/blood-2012-06-432443
Published: 2013
Includes: Supplemental data